Prevalence of Prescription Medication Use Among Non-pregnant Women of Childbearing Age and Pregnant Women in the United States: NHANES, 1999–2006

被引:0
作者
Sarah C. Tinker
Cheryl S. Broussard
Meghan T. Frey
Suzanne M. Gilboa
机构
[1] Centers for Disease Control and Prevention,National Center on Birth Defects and Developmental Disabilities
[2] Oak Ridge Institute for Science and Education,undefined
来源
Maternal and Child Health Journal | 2015年 / 19卷
关键词
Medication; Pregnancy; Women; Prescription; NHANES;
D O I
暂无
中图分类号
学科分类号
摘要
Many prescription medications have limited information regarding safety for use during pregnancy. In order to inform research on safer medication use during pregnancy, we examined prescription medication use among women in the United States. We analyzed data from the 1999–2006 National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of prescription medication use in the past 30 days among pregnant women and non-pregnant women of childbearing age (15–44 years) and to ascertain the most commonly reported prescription medications by women in these groups. We assessed how the most commonly reported medications differed among groups defined by selected demographic characteristics, including age, race/ethnicity, and markers of socioeconomic status. Prescription medication use in the past 30 days was reported by 22 % of pregnant women and 47 % of non-pregnant women of childbearing age. The most commonly reported prescription medications by NHANES participants differed somewhat by pregnancy status; allergy and anti-infective medications were more common among pregnant women, while oral contraceptives were more common among non-pregnant women. Use of prescription medication for asthma and thyroid disorders was reported by both groups. Although prescription medication use in the previous 30 days was less common among pregnant women than non-pregnant women, its use was reported among almost 1 in 4 pregnant women. Many of the most common medications reported were for the treatment of chronic medical conditions. Given the potential impact of medications on the developing fetus, our data underscore the importance of understanding the safety of these medications during pregnancy.
引用
收藏
页码:1097 / 1106
页数:9
相关论文
共 100 条
[1]  
Adam MP(2011)Evolving knowledge of the teratogenicity of medications in human pregnancy American Journal of Medical Genetics Part C, Seminars in Medical Genetics 157 175-182
[2]  
Polifka JE(2005)Medication use during pregnancy and lactation: An urgent call for public health action Journal of Women’s Health 14 104-109
[3]  
Friedman JM(2002)Teratogenicity of recently introduced medications in human pregnancy Obstetrics and Gynecology 100 465-473
[4]  
Lagoy CT(2003)Systematic identification of drugs that cause birth defects—A new opportunity The New England Journal of Medicine 349 2556-2559
[5]  
Joshi N(2013)Medications in the first trimester of pregnancy: Most common exposures and critical gaps in understanding fetal risk Pharmacoepidemiology and Drug Safety 22 1013-1018
[6]  
Cragan JD(2011)Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996–2006 Pharmacoepidemiology and Drug Safety 20 729-738
[7]  
Lo WY(2006)Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands BJOG 113 559-568
[8]  
Friedman JM(2011)Use of prescribed drugs among primiparous women: An 11-year population-based study in Denmark Clinical Epidemiology 3 149-156
[9]  
Mitchell AA(2011)Prescription drug use during pregnancy in developed countries: A systematic review Pharmacoepidemiology and Drug Safety 20 895-902
[10]  
Thorpe PG(2011)Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database Pharmacoepidemiology and Drug Safety 20 243-248